Healthcare / Diagnostics & ResearchTaiwan
$11.75
+0.05 (+0.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-115.5M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$710M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-29.8%
↓Gross Margin
15.5%
↓Debt/Equity
0.79
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.4%
FCF CAGR
—
FCF margin
-21.0%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $549.1M · net income $-146.4M · FCF $-115.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $549.1M | $549.1M | $501.5M | $415.0M | $670.6M |
| Net Income | $-146.4M | $-146.4M | $-159.9M | $-102.5M | $42.4M |
| EBITDA | $-71.5M | $-71.5M | $-103.3M | $-72.7M | $110.2M |
| EPS | — | — | -3.02 | -2.11 | 0.85 |
| Gross Margin | 15.5% | 15.5% | 11.2% | 18.9% | 37.9% |
| Operating Margin | -25.9% | -25.9% | -34.0% | -30.3% | 10.9% |
| Net Margin | -26.7% | -26.7% | -31.9% | -24.7% | 6.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.79 | 0.79 | 0.58 | 0.38 | 0.22 |
| Current Ratio | 1.23 | 1.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-115.5M | $-115.5M | $-270.2M | $-101.3M | $-57.4M |
| Returns | |||||
| ROE | -29.8% | -29.8% | -25.1% | -17.7% | 7.3% |
| Valuation | |||||
| P/E | — | — | — | — | 32.26 |
| EV/EBITDA | — | — | — | — | 12.42 |
| P/B | 1.45 | 1.45 | 1.99 | 3.07 | 2.34 |
| Growth & Yield | |||||
| Revenue Growth | 9.5% | 9.5% | 20.8% | -38.1% | — |
| EPS Growth | — | — | -43.1% | -347.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.02 → n/d
Residual
-41.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.